top of page

Innovations for Vaccine R&D


at a glance


Innovations for Vaccine R&D


01 September 2021 to 28 February 2027


European Vaccine Initiative


IMI2 Innovative Medicines Initiative, European Union and EFPIA


38.5 Mio Euro (18.6 Mio IMI, 19.9 Mio EFPIA)


Innovations to accelerate vaccine development and manufacture

Inno4vac is a new interdisciplinary project funded by the Innovative Medicines Initiative 2 (IMI2) focus on the design and application of new and highly advanced predictive models to allow a faster development and manufacturing of novel vaccines. It is coordinated by the European Vaccine Initiative, with the support from the Sclavo Vaccines Association as scientific coordination, and involves 41 partners from 11 different European countries, including 37 academic institutions and SMEs, as well as GSK, Sanofi Pasteur, CureVac and Takeda as industry partners.
Four main areas will be addressed by Inno4vac in an integrated manner:
(1) artificial intelligence will be used for in silico vaccine immune response and efficacy prediction;
(2) a modular computational platform will be developed for in silico modelling of vaccine bio-manufacturing and stability testing;
(3) new and improved controlled human infection models (CHIM) of influenza, Respiratory Syncytial Virus (RSV) and Clostridium difficile will be established to enable early vaccine efficacy evaluation, and
(4) novel cell-based human in vitro 3D models will be developed to reliably predict immune protection.



Curevac AG (Germany); Glaxosmithkline Biologicals SA (Belgium); Sanofi Pasteur SA (France) Takeda Pharmaceuticals International AG (Switzerland); Academisch Ziekenhuis (Netherlands); Association Internationale De Standardisation Biologique Pour L'Europe (Iabs-Eu, France); Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel (Germany); Danmarks Tekniske Universitet (Denmark); Eberhard Karls Universitaet Tuebingen (Germany); European Vaccine Initiative (Germany); Forschungszentrum Julich (Germany); Goeteborgs Universitet (Sweden); Helmholtz-Zentrum Fur Infektionsforschung (Germany); Imperial College Of Science Technology And Medicine (United Kingdom); Inesc Tec - Instituto De Engenhariade Sistemas E Computadores, Tecnologia E Ciencia (Portugal); Julius-Maximilians-Universitat Wurzburg (Germany); Klinikum Der Universitaet Zu Koeln (Germany); Lunds Universitet (Sweden); Medicines And Healthcare Products Regulatory Agency (United Kingdom); Nova Id Fct - Associacao Para A Inovacao E Desenvolvimento Da Fct (Portugal); Rijksinstituut Voor Volksgezondheid En Milieu (Netherlands); Sciensano (Belgium); Sclavo Vaccines Association (Italy); Stiftung Tieraerztliche Hochschule Hannover (Germany); The University Of Nottingham (United Kingdom); Universita Degli Studi Di Siena (Italy); Universitatsklinikum Jena (Germany); Universiteit Utrecht (Netherlands); Universitetet I Bergen, (Norway); Universitetet I Oslo (Norway); University College London (United Kingdom); University Of Oxford (United Kingdom); 2-Control Aps (Denmark); Enpicom BV (Netherlands); Insilico Biotechnology AG (Germany); Meyer Chroma Technology Aps (Denmark); Pharmalex Belgium (Belgium); Stichting Centre For Human Drug Research (Netherlands); Viroclinics Biosciences BV (Netherlands); Vismederi SRL (Italy);

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007799. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This communication reflects the authors' view(s) and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

bottom of page